Blog: AYTU BIOPHARMA, INC : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K) –

Item 7.01. Regulation FD Disclosure

On January 25, 2023, Aytu BioPharma, Inc. (the “Company”) issued a press release
titled “Aytu BioPharma Regains Nasdaq Bid Price Compliance.”

A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K. The information in this Item 7.01 and the exhibit attached hereto
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that Section, or incorporated by reference into any of the
Company’s filings under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in any such

Item 8.01.  Other Events

On January 23, 2023, the Company received notification from the staff (the
“Staff”) of The Nasdaq Stock Market (“Nasdaq”) that the Company regained
compliance with Listing Rule 5550(a)(2) (the “Rule”), which requires a minimum
bid price of $1.00 per share. The Staff notified the Company that it has
regained compliance with the Rule and it has closed the matter. The Company is
now fully compliant with all Nasdaq listing rules.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit    Description
99.1         Press release dated January 25, 2023
104        Cover Page Interactive Data File (formatted as inline XBRL)

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s